Researchers have uncovered a new understanding of levodopa-induced dyskinesia, a common side effect in Parkinson’s patients, ...

University of Arizona researchers have revealed new insights into one of the most common complications faced by Parkinson's ...

University of Arizona researchers uncovered how levodopa-induced dyskinesia disrupts motor cortex function in Parkinson’s ...

Now, Vyalev (foscarbidopa and foslevodopa) has become the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's ...

The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

Tavapadon is the first and only selective D1/D5 receptor partial agonist under investigation for Parkinson's and is being studied both as a monotherapy and adjunctive therapy to levodopa ...

Dec. 23, 2024 — The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress ...

Roche (OTCQX:RHHBY) announced Thursday that prasinezumab, its experimental therapy developed with Prothena Corporation ...

Prasinezumab missed statistical significance in delaying motor progression in early Parkinson's (HR=0.84, p=0.0657).